US 11,981,703 B2
Polynucleotide constructs
Sukumar Sakamuri, San Diego, CA (US); Curt W. Bradshaw, San Diego, CA (US); Laxman Eltepu, San Diego, CA (US); Bryan R. Meade, San Diego, CA (US); and Son Lam, San Diego, CA (US)
Assigned to SIRIUS THERAPEUTICS, INC., Cambridge, MA (US)
Appl. No. 16/326,542
Filed by Sirius Therapeutics, Inc., Boston, MA (US)
PCT Filed Aug. 17, 2017, PCT No. PCT/US2017/047447
§ 371(c)(1), (2) Date Feb. 19, 2019,
PCT Pub. No. WO2018/035380, PCT Pub. Date Feb. 22, 2018.
Claims priority of provisional application 62/376,182, filed on Aug. 17, 2016.
Prior Publication US 2019/0202855 A1, Jul. 4, 2019
Int. Cl. C07H 21/00 (2006.01); C07F 9/24 (2006.01); C07F 9/6558 (2006.01); C07F 9/6561 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01); C12N 15/85 (2006.01)
CPC C07H 21/00 (2013.01) [C07F 9/2408 (2013.01); C07F 9/65586 (2013.01); C07F 9/65616 (2013.01); C07H 21/02 (2013.01); C07H 21/04 (2013.01); C12N 15/113 (2013.01); C12N 15/85 (2013.01); C12N 2310/14 (2013.01)] 13 Claims
 
1. A polynucleotide construct or a salt thereof, comprising a linker conjugated to a polynucleotide and to a plurality of targeting moieties, wherein prior to conjugation of the targeting moieties, the linker has the structure X2,

OG Complex Work Unit Chemistry
and wherein conjugation of the targeting moieties to the linker occurs through one or more of the alkyne moieties of X2, and
wherein each of the targeting moieties comprises an N-acetyl galactosamine (GalNAc).